HCPCS Level II J0715: Injection, ceftizoxime sodium, per 500 mg - OpenPayer

Summary & Overview

HCPCS Level II J0715: Injection, ceftizoxime sodium, per 500 mg

HCPCS Level II code J0715 designates the injectable antibiotic ceftizoxime sodium, billed per 500 mg vial. Nationally, injectable antimicrobial codes like J0715 are important for hospital outpatient departments, emergency care, and infusion services where parenteral therapy is administered and appropriately documented for coverage and reimbursement. This code is relevant to facility billing, pharmacy charge capture, and clinical staff involved in parenteral medication delivery.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for ceftizoxime use, typical sites of service, and common billing considerations tied to a per-vial HCPCS Level II drug code. The publication also outlines benchmarks and policy updates where available, and explains how the code is used in service lines handling injectable antibiotics. Data not available in the input will be noted explicitly in the relevant sections.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ0715HCPCS Level IIceftizoximeinjectable antibiotichospital outpatientinfusiondrug billingpharmacy charge capture

Billing Code Overview

HCPCS Level II code J0715 represents the medication ceftizoxime sodium, billed per 500 mg vial for parenteral administration. This code is used to report the drug product itself when administered as an injection.

Service type: Injectable antimicrobial therapy
Typical site of service: Hospital outpatient departments, emergency departments, infusion centers, and other settings where parenteral antibiotics are administered

Clinical & Coding Specifications

Clinical Context

A 68-year-old male with a history of chronic obstructive pulmonary disease and recently hospitalized for community-acquired pneumonia presents to an outpatient infusion center for intravenous antibiotic therapy after initial stabilization. The infectious disease clinician orders parenteral ceftizoxime sodium to treat a Gram-negative lower respiratory tract infection suspected or confirmed by sputum culture. The clinical workflow includes verification of the antibiotic order, allergy check, preparation of J0715 (ceftizoxime sodium) by pharmacy in the appropriate concentration per 500 mg vial dosing, documentation of dose and lot number, patient identification and consent, intravenous access verification (peripheral IV or existing central line), administration by a registered nurse, monitoring for infusion reactions during and for at least 30 minutes after infusion, and documentation of the administration event including start/stop times, total mg administered, and any adverse reactions. Typical sites of service are outpatient infusion centers, hospital outpatient departments, emergency departments when used for acute infections, and skilled nursing facilities for transitional care. Common patient scenarios include treatment of severe community-acquired pneumonia, complicated urinary tract infections, intra-abdominal infections, or empiric coverage in sepsis where ceftizoxime is an appropriate agent.

Coding Specifications

Modifier	Description	When to Use
`22`

HCPCS J2001: Lidocaine HCl Injection for Intravenous Infusion, 10 mg

HCPCS-J7030-INFUSION-NORMAL-SALINE-1000CC

HCPCS J7030: Infusion of Normal Saline Solution, 1000 cc

HCPCS-J3121-TESTOSTERONE-ENANTHATE-INJECTION-1MG

HCPCS J3121: Injection, Testosterone Enanthate, 1 mg

HCPCS-J2940-SOMATREM-INJECTION-1MG

HCPCS Level II J2940: Injection, Somatrem, 1 mg

HCPCS-J1595-GLATIRAMER-ACETATE-INJECTION-20MG

HCPCS Level II J1595: Injection, glatiramer acetate, 20 mg

HCPCS-J0350-ANISTREPLASE-INJECTION-30-UNITS

HCPCS J0350: Injection, Anistreplase, per 30 Units

HCPCS-J0702-BETAMETHASONE-INJECTION-3MG-ACETATE-SODIUM-PHOSPHATE

HCPCS J0702: Betamethasone Injection, Acetate 3 mg / Sodium Phosphate 3 mg

HCPCS-J2820-SARGRAMOSTIM-50MCG-INJECTION

HCPCS J2820: Sargramostim (GM-CSF) Injection, 50 mcg

HCPCS-J0612-CALCIUM-GLUCONATE-INJECTION-10MG

HCPCS J0612: Injection, Calcium Gluconate, 10 mg

HCPCS-J8610-METHOTREXATE-ORAL-2-5-MG

HCPCS Level II J8610: Methotrexate, Oral, 2.5 mg

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`2080S0105X`	Infectious Disease Specialist	Typically directs antibiotic selection and monitors therapy.
`207Q00000X`	Pulmonology	Manages respiratory infections requiring parenteral therapy such as pneumonia.
`363L00000X`	Hematology/Oncology	May administer IV antibiotics in immunocompromised patients or inpatient infusion settings.
`163W00000X`	Emergency Medicine	Initiates parenteral antibiotics in acute presentations prior to outpatient transfer.
`174400000X`	Internal Medicine	Hospitalists and internists commonly order and manage IV antibiotic courses.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J18.9`	Pneumonia, unspecified organism	Common indication for parenteral ceftizoxime when treating moderate-to-severe community-acquired pneumonia requiring IV antibiotics.
`N39.0`	Urinary tract infection, site not specified	Complicated UTIs may require IV ceftizoxime for Gram-negative coverage.
`K35.80`	Acute appendicitis without generalized peritonitis	Intra-abdominal infections may be treated with ceftizoxime as part of perioperative or postoperative antibiotic therapy.
`A41.9`	Sepsis, unspecified organism	Empiric broad-spectrum IV antibiotics including ceftizoxime may be used pending cultures in certain sepsis presentations.
`K65.9`	Peritonitis, unspecified	Intra-abdominal source control plus IV antibiotics such as ceftizoxime is a common management step.
`A49.2`	Pseudomonas infection, site unspecified	When culture or clinical suspicion indicates Gram-negative pathogens treatable with ceftizoxime.
`L03.116`	Cellulitis of right lower limb	Severe skin and soft tissue infections with Gram-negative involvement may prompt IV ceftizoxime.
`B96.2`	Escherichia coli as the cause of diseases classified elsewhere	Targeted therapy for E. coli infections often includes third-generation cephalosporins like ceftizoxime.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used for reporting the initial IV infusion time when `J0715` is administered as part of a monitored infusion lasting up to 1 hour.
`96366`	Intravenous infusion, each additional hour	Used when the infusion of `J0715` or concurrent IV therapy extends beyond the first hour.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used if `J0715` is administered intramuscularly in a specific clinical setting, though parenteral IV administration is more typical.
`36415`	Collection of venous blood by venipuncture	Often performed before or during therapy to obtain cultures or labs guiding continued use of `J0715`.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M level for outpatient visits preceding or following infusion of `J0715` in an infusion center or clinic.

OpenPayer